WO2023021480 - METHOD OF TREATING PARKINSON'S DISEASE

National phase entry:
Publication Number WO/2023/021480
Publication Date 23.02.2023
International Application No. PCT/IB2022/057814
International Filing Date 19.08.2022
Title **
[English] METHOD OF TREATING PARKINSON'S DISEASE
[French] PROCÉDÉ DE TRAITEMENT DE LA MALADIE DE PARKINSON
Applicants **
CLEXIO BIOSCIENCES LTD.
Inventors
MIMROD, Dorit
BERKOVICH, Elijahu
IZGELOV, Dvora
Priority Data
63/234,801   19.08.2021   US
63/315,183   01.03.2022   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2458
EPO Filing, Examination, Granting14413
Japan Filing, Examination, Granting2549
South Korea Filing, Examination, Granting2826
USA Filing, Examination, Granting6140
MasterCard Visa
Total: 28,386

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] The disclosure is directed to methods of treating Parkinson's disease comprising administration of a capsule comprising an anti-parkinsonian medication and where the capsule's length is at least about 29mm and the capsule's width at least about 9.5mm.[French] L'invention concerne des procédés de traitement de la maladie de Parkinson comprenant l'administration d'une capsule comprenant un médicament anti-parkinsonien, la longueur de la capsule étant d'au moins environ 29 mm et la largeur de la capsule étant d'au moins environ 9,5 mm.

Rejoining the server...